Clinical Trial Update: Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRA-027 Administered to Healthy Japanese Females [Phase 1]

View source ↗

Summary

A completed Phase 1 study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of PRA-027 in healthy Japanese females.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Fibroids

Drugs mentioned

• PRA-027

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Uterine Leiomyomata (Fibroids) | Phase 1 | Status: COMPLETED